Colorectal cancer (CRC) is often diagnosed at an advanced stage when tumor cell
dissemination has taken place. Chemo-and targeted therapies provide only a limited …

Importance Primary tumor location is emerging as an important prognostic factor owing to
distinct biological features. However, the side of origin of colon cancer (CC) still does not …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Purpose: Evaluate response of mismatch repair–deficient (dMMR) rectal cancer to
neoadjuvant chemotherapy. Experimental Design: dMMR rectal tumors at Memorial Sloan …

Microsatellite instability (MSI) is a molecular marker of a deficient mismatch repair (MMR)
system and occurs in approximately 15% of colorectal cancers (CRCs), more frequently in …

Background Precision cancer medicine depends on defining distinct tumour subgroups
using biomarkers that may occur at very modest frequencies. One such subgroup comprises …

Background TNM staging alone does not accurately predict outcome in colon cancer (CC)
patients who may be eligible for adjuvant chemotherapy. It is unknown to what extent the …

Background Characterisation of colorectal cancer (CRC) genomes by next-generation
sequencing has led to the discovery of novel recurrently mutated genes. Nevertheless …

The colorectal cancer (CRC) patients with microsatellite instability (MSI) have distinct
clinicopathological characteristics consisting of factors predicting positive and negative …

Centrosomes are the major microtubule organising centres of animal cells. Deregulation in
their number occurs in cancer and was shown to trigger tumorigenesis in mice. However, the …